ASP Isotopes, Inc. (ASPI)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-10-29
$2.13+4.93%
Close 2026-10-29 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-10-29
Research Workspace
Put ASPI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Materials: fringe margins under pressure (0q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 573% over the past year.
View GrowthManagement screens weak on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 523% growth a year, above the roughly 97% analysts expect, leaving little room for error.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 82% in its worst 12-month stretch.
View RiskASPI's case rests on commissioning helium production and advancing Quantum Leap Energy toward public listing. Its recent earnings and revenue trend is unavailable, and the latest result is unrecorded. The shares trade at 9× sales versus 1× for peers. Expectations look full because the market prices in more growth than our forecast. A next-quarter miss probability of 51% makes disappointing results a specific risk. Peer multiples imply a price about 523% below where it trades. This read is provisional.
Trailing returns as of 2026-10-29. ASPI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering ASPI (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare ASPI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ASPI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Diversified Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put ASPI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete Phase 1 helium commissioning and ramp production
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Stable liquid helium production supports Phase 1 commissioning and ramp, but does not establish sustained commercial output.
Advances: Advance Quantum Leap Energy toward public listing
Merger supports growth objective for Quantum Leap Energy.
Advances: Advance commercial shipments of enriched isotopes in 2026
Conference highlights commitment to commercial shipments of isotopes.
Advances: Initial commercial shipments of Silicon-28 in Q3 2026
Facility upgrades signal progress towards commercial shipments.
Advances: Initial commercial shipments of Silicon-28 in Q3 2026
Restarting facility supports timeline for Silicon-28 production.